9EN Stock Overview
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pharvaris N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.20 |
| 52 Week High | US$29.60 |
| 52 Week Low | US$7.25 |
| Beta | -3.12 |
| 1 Month Change | 0% |
| 3 Month Change | -23.19% |
| 1 Year Change | 155.42% |
| 3 Year Change | 10.99% |
| 5 Year Change | n/a |
| Change since IPO | -1.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9EN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 21.8% | 3.9% | 2.0% |
| 1Y | 155.4% | -28.2% | 2.0% |
Return vs Industry: 9EN exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 9EN exceeded the German Market which returned 2% over the past year.
Price Volatility
| 9EN volatility | |
|---|---|
| 9EN Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9EN's share price has been volatile over the past 3 months.
Volatility Over Time: 9EN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Berndt Axel Modig | pharvaris.com |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Pharvaris N.V. Fundamentals Summary
| 9EN fundamental statistics | |
|---|---|
| Market cap | €1.17b |
| Earnings (TTM) | -€100.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.6x
P/E RatioIs 9EN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9EN income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €100.88m |
| Earnings | -€100.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9EN perform over the long term?
See historical performance and comparison